Observational Prospective Registry of the Efficacy, Safety, and Adherence to Therapy of Infergen (Interferon Alfacon 1) in Patients Chronically Infected With Hepatitis C Virus
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 07 Sep 2015
At a glance
- Drugs Interferon alfacon-1 (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms REACH-SVR
- Sponsors Kadmon Pharmaceuticals; Three Rivers Pharmaceuticals
- 02 Sep 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 23 May 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.